Therapeutic drug monitoring (TDM) for anti-tuberculosis

Maharita AR, Izzuna MMG
Record ID 32018002431
English
Authors' objectives: To assess the efficacy/ effectiveness, safety and cost-effectiveness of therapeutic drug monitoring (TDM) in tuberculosis treatment.
Authors' results and conclusions: Concentration level of the first-line anti-TB drugs was not associated with patient outcome. However, for second-line anti-TB drugs, TDM was used to ensure the therapeutic drug level especially in narrow therapeutic range anti-TB drug. The TDM also play a crucial role in safety as it used for detection of any possible over dosage or low dosage of anti-tuberculosis. As for now, no cost-effectiveness study retrieved related to TDM for anti-TB drug.
Authors' recommendations: Therapeutic drug monitoring in tuberculosis patients have no added benefit in patients on first line anti-TB. Hence it should not be routinely conducted. However, for patients on second line anti-TB, TDM may be used to monitor plasma drug concentration, dosing adjustment and to avoid toxicity level.
Authors' methods: A systematic review was conducted. Review protocol and search strategy was developed by the main author and Information Specialist. The following electronic databases were searched through the Ovid interface: Ovid interface: Ovid MEDLINE® In-Process & Other Non-Indexed Citations and Ovid MEDLINE® 1946 to 10th August 2021. Parallel searches were run in PubMed, US FDA, CADTH, and INAHTA database. No limits were applied to the search. Any additional articles were identified from reviewing the references of retrieved articles. The last search was performed on 12th August 2021.
Authors' identified further research: There were included studies in this review had small sample size which might not reflect the whole population of interest.
Details
Project Status: Completed
Year Published: 2021
URL for published report: https://www.moh.gov.my/index.php/database_stores/store_view_page/30/377
Requestor: Ministry of Health, decision-making committee
English language abstract: An English language summary is available
Publication Type: Mini HTA
Country: Malaysia
MeSH Terms
  • Tuberculosis
  • Drug Monitoring
  • Antitubercular Agents
Keywords
  • Tuberculosis
  • Anti-tuberculosis
  • Therapuetic drug monitoring
Contact
Organisation Name: Malaysian Health Technology Assessment
Contact Address: Malaysian Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, Level 4, Block E1, Parcel E, 62590 Putrajaya Malaysia Tel: +603 8883 1229
Contact Name: htamalaysia@moh.gov.my
Contact Email: htamalaysia@moh.gov.my
Copyright: Malaysian Health Technology Assessment Section (MaHTAS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.